Mon . 20 Aug 2020
TR | RU | UK | KK | BE |


narcolepsy, narcolepsy symptoms
Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles1 Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy These spells can be brought on by strong emotions Less commonly there may be inability to move or vivid hallucinations while falling asleep or waking up People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse1

The exact cause of narcolepsy is unknown with potentially several causes13 In up to 10% of cases there is a family history of the disorder Often those affected have low levels of the neuropeptide orexin which may be due to an autoimmune disorder Trauma, infections, toxins, or psychological stress may also play a role Diagnosis is typically based on the symptoms and sleep studies, after ruling out other potential causes Excessive daytime sleepiness can also be caused by other sleep disorders such as sleep apnea, major depressive disorder, anemia, heart failure, drinking alcohol, and not getting enough sleep Cataplexy may be mistaken for seizures1

While there is no cure, a number of lifestyle changes and medications may help Lifestyle changes include taking regular short naps and sleep hygiene Medications used include modafinil, sodium oxybate, and methylphenidate While initially effective, tolerance to the benefits may develop over time Tricyclic antidepressants and selective serotonin reuptake inhibitors SSRIs may improve cataplexy1

About 02 to 600 per 100,000 people are affected2 The condition often begins in childhood Men and women are affected equally Untreated narcolepsy increases the risk of motor vehicle collisions and falls1 The term narcolepsy is from the French narcolepsie The French term was first used in 1880 by Jean-Baptiste-Édouard Gélineau who used the Greek νάρκη narkē meaning "numbness" and λῆψις lepsis meaning "attack"4

Play media Video explanation


  • 1 Signs and symptoms
  • 2 Causes
    • 21 Genetics
    • 22 Evolution
    • 23 Vaccine
  • 3 Pathophysiology
  • 4 Diagnosis
    • 41 Classification
  • 5 Treatment
  • 6 Epidemiology
  • 7 Society and culture
  • 8 Research
    • 81 Histamine-directed medications
    • 82 GABA-directed medications
      • 821 Flumazenil
      • 822 Clarithromycin
    • 83 Orexin receptor agonists
    • 84 L-carnitine
  • 9 References
  • 10 Sources
  • 11 External links

Signs and symptomsedit

There are two main characteristics of narcolepsy: excessive daytime sleepiness and abnormal REM sleep5 The first, excessive daytime sleepiness EDS, occurs even after adequate night time sleep A person with narcolepsy is likely to become drowsy or fall asleep, often at inappropriate times and places, or just be very tired throughout the day Narcoleptics are not able to experience the amount of restorative deep sleep that healthy people experience – they are not "over-sleeping" In fact, narcoleptics live their entire lives in a constant state of extreme sleep deprivation

Daytime naps may occur with little warning and may be physically irresistible These naps can occur several times a day They are typically refreshing, but only for a few hours or less Vivid dreams may be experienced on a regular basis, even during very brief naps Drowsiness may persist for prolonged periods or remain constant In addition, night-time sleep may be fragmented, with frequent awakenings A second prominent symptom of narcolepsy is abnormal REM sleep Narcoleptics are unique in that they enter into the REM phase of sleep in the beginnings of sleep, even when sleeping during the day5

The classic symptoms of the disorder, often referred to as the "tetrad of narcolepsy," are cataplexy, sleep paralysis, hypnagogic hallucinations, and excessive daytime sleepiness6 Other symptoms may include automatic behaviors and night-time wakefulness578 These symptoms may not occur in all patients

  • Cataplexy is an episodic loss of muscle function, ranging from slight weakness such as limpness at the neck or knees, sagging facial muscles, weakness at the knees often referred to as "knee buckling",9 or inability to speak clearly, to a complete body collapse Episodes may be triggered by sudden emotional reactions such as laughter, anger, surprise, or fear, and may last from a few seconds to several minutes The person remains conscious throughout the episode In some cases, cataplexy may resemble epileptic seizurescitation needed Usually speech is slurred and vision is impaired double vision, inability to focus, but hearing and awareness remain normal Cataplexy also has a severe emotional impact on narcoleptics, as it can cause extreme anxiety, fear, and avoidance of people or situations that might elicit an attackcitation needed Cataplexy is generally considered to be unique to narcolepsy and is analogous to sleep paralysis in that the usually protective paralysis mechanism occurring during sleep is inappropriately activated The opposite of this situation failure to activate this protective paralysis occurs in rapid eye movement behavior disorder
  • Periods of wakefulness at night5
  • Sleep paralysis is the temporary inability to talk or move when waking or less often, when falling asleep It may last a few seconds to minutes This is often frightening but is not dangerous
  • Hypnagogic hallucinations are vivid, often frightening, dreamlike experiences that occur while dozing or falling asleep Hypnopompic hallucinations refer to the same sensations while awakening from sleep These hallucinations may manifest in the form of visual or auditory sensations5
  • Automatic behaviors occur when a person continues to function talking, putting things away, etc during sleep episodes but awakens with no memory of performing such activities It is estimated that up to 40 percent of people with narcolepsy experience automatic behavior during sleep episodes

In most cases, the first symptom of narcolepsy to appear is excessive and overwhelming daytime sleepiness The other symptoms may begin alone or in combination months or years after the onset of the daytime naps There are wide variations in the development, severity, and order of appearance of cataplexy, sleep paralysis, and hypnagogic hallucinations in individuals Only about 20 to 25 percent of people with narcolepsy experience all four symptoms The excessive daytime sleepiness generally persists throughout life, but sleep paralysis and hypnagogic hallucinations may not A rare subset of narcoleptics also experience a heightened sense of taste and smell known as the supertaster phenomenoncitation needed

Many people with narcolepsy also suffer from insomnia for extended periods of time The excessive daytime sleepiness and cataplexy often become severe enough to cause serious problems in a person's social, personal, and professional life Normally, when an individual is awake, brain waves show a regular rhythm When a person first falls asleep, the brain waves become slower and less regular, which is called non-rapid eye movement NREM sleep After about an hour and a half of NREM sleep, the brain waves begin to show a more active pattern again, called REM sleep rapid eye movement sleep, when most remembered dreaming occurs Associated with the EEG-observed waves during REM sleep, muscle atonia is present called REM atoniacitation needed

In narcolepsy, the order and length of NREM and REM sleep periods are disturbed, with REM sleep occurring at sleep onset instead of after a period of NREM sleep Also, some aspects of REM sleep that normally occur only during sleep, like lack of muscular control, sleep paralysis, and vivid dreams, occur at other times in people with narcolepsy For example, the lack of muscular control can occur during wakefulness in a cataplexy episode; it is said that there is intrusion of REM atonia during wakefulness Sleep paralysis and vivid dreams can occur while falling asleep or waking up Simply put, the brain does not pass through the normal stages of dozing and deep sleep but goes directly into and out of rapid eye movement REM sleepcitation needed

As a consequence night time sleep does not include as much deep sleep, so the brain tries to "catch up" during the day, hence EDS People with narcolepsy may visibly fall asleep at unpredicted moments such motions as head bobbing are common People with narcolepsy fall quickly into what appears to be very deep sleep, and they wake up suddenly and can be disoriented when they do dizziness is a common occurrence They have very vivid dreams, which they often remember in great detail People with narcolepsy may dream even when they only fall asleep for a few seconds Along with vivid dreaming, people with narcolepsy are known to have audio or visual hallucinations prior to falling asleep

Narcoleptics can gain excess weight; children can gain 20 to 40 lb 9 to 18 kg when they first develop narcolepsy; in adults the body-mass index is about 15% above average1011


The exact cause of narcolepsy is unknown, and it may be caused by several distinct factors13 Part of the mechanism involves the loss of orexin-releasing neurons within the lateral hypothalamus1213 In up to 10% of cases there is a family history of the disorder1 There is a strong link with certain genetic variants12 In addition to genetic factors, low levels of orexin peptides have been correlated with a past history of infection, diet, contact with toxins such as pesticides, and brain injuries due to brain tumors or strokes125


The primary genetic factor that has been strongly implicated in the development of narcolepsy involves an area of chromosome 6 known as the human leukocyte antigen HLA complex1214 Specific variations in HLA genes are strongly correlated with the presence of narcolepsy;12 however, these variations are not required for the condition to occur and sometimes occur in individuals without narcolepsy1215 These genetic variations in the HLA complex are thought to increase the risk of an auto-immune response to orexin-releasing neurons in the lateral hypothalamus121315

The allele HLA-DQB106:02 of the human gene HLA-DQB1 was reported in more than 90% of patients, and alleles of other HLA genes such as HLA-DQA101:02 have been linked A 2009 study found a strong association with polymorphisms in the TRAC gene locus dbSNP IDs rs1154155, rs12587781, and rs126364616 A 2013 review article reported additional but weaker links to the loci of the genes TNFSF4 rs7553711, Cathepsin H rs34593439, and P2RY11-DNMT1 rs230579517 Another gene locus that has been associated with narcolepsy is EIF3G rs382678418


Narcolepsy may represent an evolutionary atavismcitation needed According to a hypothesis REM sleep is an evolutionary transformation of a well-known defensive mechanism, the tonic immobility reflex1920 This reflex, also known as animal hypnosis or death feigning, functions as the last line of defense against an attacking predator and consists of the total immobilization of the animal: the animal appears dead cf "playing possum" The neurophysiology and phenomenology of this reaction shows striking similarities to REM sleep, a fact which betrays a potential evolutionary kinship For example, both reactions exhibit brainstem control, paralysis, sympathetic activation, and thermoregulatory changes This hypothesis, which integrates many research findings into a unified and evolutionarily well informed framework, also sheds light on the phenomenon of narcolepsy19


A link between GlaxoSmithKline's H1N1 flu vaccine Pandemrix and childhood narcolepsy was investigated due to increased prevalence of narcolepsy in Irish, Finnish and Swedish children after vaccinations Finland's National Institute of Health and Welfare recommended that Pandemrix vaccinations be suspended pending further investigation into 15 reported cases of children developing narcolepsy2122 In Finland in mid-November 2010, 37 cases of children's narcolepsy had been reported by doctors This can be compared to the normal average of 3 cases of children's narcolepsy per year23 "The incidence of narcolepsy with cataplexy in children/adolescents in the Swedish population increased during the pandemic and vaccination period, with a rapid decline in incidence during the post pandemic period" They concluded that these results "provide strengthened evidence that vaccination with Pandemrix during the pandemic period could be associated with an increase in the risk for narcolepsy with cataplexy in predisposed children/adolescents 19 years and younger"24 In 2013, the link between Pandemrix and narcolepsy was confirmed by a registry study by the Swedish Medical Products Agency, with a three-fold increase in risk for people under the age of 2025


Orexin, otherwise known as hypocretin, is a neuropeptide that acts within the brain to regulate appetite and wakefulness as well as a number of other cognitive and physiological processes122627 While there are billions of cells in the human brain, only 10,000–20,000 neurons secrete orexin peptides;5 all of these neurons project out of the lateral hypothalamus12 Loss of these orexin-producing neurons causes narcolepsy and most individuals with narcolepsy have a reduced number of these neurons in their brains121315

The neural control of normal sleep states and the relationship to narcolepsy are only partially understood In humans, narcoleptic sleep is characterized by a tendency to go abruptly from a waking state to REM sleep with little or no intervening non-REM sleep The changes in the motor and proprioceptive systems during REM sleep have been studied in both human and animal models During normal REM sleep, spinal and brainstem alpha motor neuron hyperpolarization produces almost complete atonia of skeletal muscles via an inhibitory descending reticulospinal pathway Acetylcholine may be one of the neurotransmitters involved in this pathway In narcolepsy, the reflex inhibition of the motor system seen in cataplexy has features normally seen only in normal REM sleep1


Diagnosis is relatively easy when all the symptoms of narcolepsy are present, but if the sleep attacks are isolated and cataplexy is mild or absent, diagnosis is more difficult It is also possible for cataplexy to occur in isolationcitation needed Three tests that are commonly used in diagnosing narcolepsy are the polysomnogram, the multiple sleep latency test MSLT, and administration of the Epworth Sleepiness Scale These tests are usually performed by a sleep specialist The polysomnogram involves continuous recording of sleep brain waves and a number of nerve and muscle functions during night time sleep When tested, people with narcolepsy fall asleep rapidly, enter REM sleep early, and may often awaken during the night The polysomnogram also helps to detect other possible sleep disorders that could cause daytime sleepiness

The Epworth Sleepiness Scale is a brief questionnaire that is administered to determine the likelihood of the presence of a sleep disorder, including narcolepsy For the multiple sleep latency test, a person is given a chance to sleep every 2 hours during normal wake times The patient is taken in usually for an overnight sleep study The following day the patient will have multiple tests where they will be told to nap after a full nights sleep usually eight hours Observations are made of the time taken to reach various stages of sleep sleep onset latency This test measures the degree of daytime sleepiness and also detects how soon REM sleep begins Again, people with narcolepsy fall asleep rapidly and enter REM sleep early Occasionally, a multiple sleep latency test can result in a false-negative for a narcoleptic28

The system which regulates sleep, arousal, and transitions between these states in humans is composed of three interconnected subsystems: the orexin projections from the lateral hypothalamus, the reticular activating system, and the ventrolateral preoptic nucleus13 In narcoleptic individuals, these systems are all associated with impairments due to a greatly reduced number of hypothalamic orexin projection neurons and significantly fewer orexin neuropeptides in cerebrospinal fluid and neural tissue, compared to non-narcoleptic individuals13 Those with narcolepsy generally experience the REM stage of sleep within five minutes of falling asleep, while people who do not have narcolepsy unless they are significantly sleep deprived29 do not experience REM until after a period of slow-wave sleep, which lasts for about the first hour or so of a sleep cycle1

Measuring orexin levels in a person's cerebrospinal fluid sampled in a spinal tap may help in diagnosing narcolepsy,30 with abnormally low levels serving as an indicator of the disorder This test can be useful when MSLT results are inconclusive or difficult to interpret31


The 2001 International Classification of Sleep Disorders ICSD divides primary hypersomnia syndromes between narcolepsy, idiopathic hypersomnia, and the recurrent hypersomnias like Klein-Levin syndrome; it further divides narcolepsy into that with cataplexy and that without cataplexy32 This ICSD version defines narcolepsy as a disorder of unknown cause "that is characterized by excessive sleepiness that typically is associated with cataplexy and other REM-sleep phenomena, such as sleep paralysis and hypnagogic hallucinations" It also establishes baseline categorical standards for diagnosis of narcolepsy, through 2 sets of well defined criteria, as follows33 Minimal narcolepsy diagnostic criteria set #2:

  • A "complaint of excessive sleepiness or sudden muscle weakness"
  • Associated features that include: sleep paralysis; disrupted major sleep episode; hypnagogic hallucinations; automatic behaviors
  • Polysomnography with one or more of the following: "sleep latency less than 10 minutes;" "REM sleep latency less than 20 minutes;" an MSLT with a mean sleep latency less than 5 minutes; "two or more sleep-onset REM periods" SOREMPs
  • "No medical or mental disorder accounts for the symptoms" see hypersomnia differential diagnosis33

In the absence of clear cataplexy, it becomes much more difficult to make a firm diagnosis of narcolepsy “Various terms, such as essential hypersomnia, primary hypersomnia, ambiguous narcolepsy, atypical narcolepsy, etc, have been used to classify these patients, who may be in the developing phase of narcolepsy” 33

Since the 2001 ICSD, the classification of primary hypersomnias has been steadily evolving, as further research has shown more overlap between narcolepsy and idiopathic hypersomnia34 The 3rd edition of the ICSD is currently being finalized, and its new classification will label narcolepsy caused by orexin deficiency as “type 1 narcolepsy,” which is almost always associated with cataplexy The other primary hypersomnias will remain subdivided based on the presence of SOREMPs They will be labeled: “type 2 narcolepsy,” with 2 or more SOREMPs on MSLT; and “idiopathic hypersomnia,” with less than 2 SOREMPS35

However, “there is no evidence that the pathophysiology or therapeutic response is substantially different for hypersomnia with or without SOREMPs on the MSLT”35 Given this currently understood overlap of idiopathic hypersomnia and narcolepsy, the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders DSM-V is also updating its classification of the primary hypersomnias It reclassifies narcolepsy without cataplexy as major somnolence disorder MSD Additionally, MSD will encompass all syndromes of hypersomnolence not explained by low orexin concentrations, including idiopathic hypersomnia with and without long sleep time and long sleepers people requiring >10 hours sleep/day353637

Further complicating these updated classification schemes, overlap between narcolepsy with cataplexy and idiopathic hypersomnia has also been reported A subgroup of narcoleptics with long sleep time, comprising 18% of narcoleptics in one study, had symptoms of both narcolepsy with cataplexy and idiopathic hypersomnia long sleep time and unrefreshing naps It is believed that this subgroup might have dysfunction in multiple arousal systems, including orexin and GABA see idiopathic hypersomnia causes38


People with narcolepsy can be substantially helped, but not cured Treatment is tailored to the individual, based on symptoms and therapeutic response The time required to achieve optimal control of symptoms is highly variable and may take several months or longer Medication adjustments are frequently necessary, and complete control of symptoms is seldom possible While oral medications are the mainstay of formal narcolepsy treatment, lifestyle changes are also importantmedical citation needed

The main treatment of excessive daytime sleepiness in narcolepsy is central nervous system stimulants such as methylphenidate, amphetamine, dextroamphetamine, modafinil, and armodafinil In late 2007 an alert for severe adverse skin reactions to modafinil was issued by the FDA39

Another drug that is used is atomoxetine, a non-stimulant and a norepinephrine reuptake inhibitor NRI, which has no addiction liability or recreational effects In many cases, planned regular short naps can reduce the need for pharmacological treatment of the EDS, but only improve symptoms for a short duration A 120-minute nap provided benefit for 3 hours in patient alertness whereas a 15-minute nap provided no benefit40 Daytime naps are not a replacement for nighttime sleep Ongoing communication between the health care provider, patient, and the patient's family members is important for optimal management of narcolepsy

Another FDA-approved treatment option for narcolepsy is sodium oxybate,41 also known as sodium gamma-hydroxybutyrate GHB It can be used for cataplexy associated with narcolepsy and excessive daytime sleepiness associated with narcolepsy41424344

Narcolepsy has sometimes been treated with selective serotonin reuptake inhibitors and tricyclic antidepressants, such as clomipramine, imipramine, or protriptyline, as well as other drugs that suppress REM sleep45 Venlafaxine, an antidepressant which blocks the reuptake of serotonin and norepinephrine, has shown usefulness in managing symptoms of cataplexy,46 however, it has notable side-effects including sleep disruption47


In the United States, it is estimated that this condition afflicts as many as 200,000 Americans,48 but fewer than 50,000 are diagnosed It is as widespread as Parkinson's disease or multiple sclerosis and more prevalent than cystic fibrosis, but it is less well known Narcolepsy is often mistaken for depression, epilepsy, or the side effects of medications It can also be mistaken for poor sleeping habits, recreational drug use, or laziness Narcolepsy can occur in both men and women at any age, although its symptoms are usually first noticed in teenagers or young adults There is strong evidence that narcolepsy may run in families; around 10 percent of people diagnosed with narcolepsy with cataplexy have a close relative with this neurological disorder1 While narcolepsy symptoms are often confused with depression, there is a link between the two disorders Research studies have mixed results on co-occurrence of depression in narcolepsy patients - the numbers quoted by different studies are anywhere between 6% and 50%49

Narcolepsy has its typical onset in adolescence and young adulthood There is an average 15-year delay between onset and correct diagnosis which may contribute substantially to the disabling features of the disorder Cognitive, educational, occupational, and psychosocial problems associated with the excessive daytime sleepiness of narcolepsy have been documented For these to occur in the crucial teen years when education, development of self-image, and development of occupational choice are taking place is especially devastating While cognitive impairment does occur, it may only be a reflection of the excessive daytime somnolencecitation needed

The prevalence of narcolepsy is about 1 per 2,000 persons48 It is a reason for patient visits to sleep disorder centers, and with its onset in adolescence, it is also a major cause of learning difficulty and absenteeism from school Normal teenagers often already experience excessive daytime sleepiness because of a maturational increase in physiological sleep tendency accentuated by multiple educational and social pressures; this may be disabling with the addition of narcolepsy symptoms in susceptible teenagers In clinical practice, the differentiation between narcolepsy and other conditions characterized by excessive somnolence may be difficult Treatment options are currently limited There is a paucity in the literature of controlled double-blind studies of possible effective drugs or other forms of therapy Mechanisms of action of some few available therapeutic agents have been explored but detailed studies of mechanisms of action are needed before new classes of therapeutic agents can be developed Narcolepsy is an underdiagnosed condition in the general population This is partly because its severity varies, so it can be mistaken for other illnesses very easily Some people with narcolepsy do not suffer from loss of muscle control

Society and cultureedit

See also: List of people with narcolepsy

In 2015, it was reported that the British Department of Health was paying for sodium oxybate medication for 80 people who are taking legal action over problems linked to the use of the Pandemrix swine flu vaccine at a cost of £12,000 a year Sodium oxybate is not available to people with narcolepsy through the National Health Service50


Histamine-directed medicationsedit

"Based on the role of histamine in keeping people awake and hence the common side effect of anti-histamines such as diphenhydramine causing sleepiness, medications that act on histamine are under development for the treatment of excessive sleepiness"51 It remains to be seen whether these H3 antagonists ie, compounds such as pitolisant that promote the release of the wake-promoting amine histamine will be particularly useful as wake-promoting agents35

GABA-directed medicationsedit

Given the possible role of hyper-active GABAA receptors in the primary hypersomnias narcolepsy and idiopathic hypersomnia, medications that could counteract this activity are being studied to test their potential to improve sleepiness These currently include clarithromycin and flumazenil5253


Flumazenil is the only GABAA receptor antagonist on the market as of Jan 2013, and it is currently manufactured only as an intravenous formulation Given its pharmacology, researchers consider it to be a promising medication in the treatment of primary hypersomnias Results of a small, double-blind, randomized, controlled clinical trial were published in November 2012 This research showed that flumazenil provides relief for most patients whose CSF contains the unknown "somnogen" that enhances the function of GABAA receptors, making them more susceptible to the sleep-inducing effect of GABA For one patient, daily administration of flumazenil by sublingual lozenge and topical cream has proven effective for several years5254 A 2014 case report also showed improvement in primary hypersomnia symptoms after treatment with a continuous subcutaneous flumazenil infusion55 The supply of generic flumazenil was initially thought to be too low to meet the potential demand for treatment of primary hypersomnias56 However, this scarcity has eased, and dozens of patients are now being treated with flumazenil off-label57


In a test tube model, clarithromycin an antibiotic approved by the FDA for the treatment of infections was found to return the function of the GABA system to normal in patients with primary hypersomnias Investigators therefore treated a few patients with off-label clarithromycin, and most felt their symptoms improved with this treatment In order to help further determine whether clarithromycin is truly beneficial for the treatment of narcolepsy and idiopathic hypersomnia, a small, double-blind, randomized, controlled clinical trial was completed in 201253 "In this pilot study, clarithromycin improved subjective sleepiness in GABA-related hypersomnia Larger trials of longer duration are warranted"58 In 2013, a retrospective review evaluating longer-term clarithromycin use showed efficacy in a large percentage of patients with GABA-related hypersomnia59 “It is important to note that the positive effect of clarithromycin is secondary to a benzodiazepine antagonist-like effect, not its antibiotic effects, and treatment must be maintained”35

Orexin receptor agonistsedit

See also: Orexin receptor

Orexin-A aka hypocretin-1 has been shown to be strongly wake-promoting in animal models, but unfortunately it does not cross the blood-brain barrier Therefore, companies have developed orexin receptor antagonists, like suvorexant, for the treatment of insomnia It is also likely that an orexin-A receptor agonist will be found and developed for the treatment of hypersomnia35


Abnormally low levels of acylcarnitine have been observed in people with narcolepsy60 These same low levels have been associated with primary hypersomnia in general in mouse studies “Mice with systemic carnitine deficiency exhibit a higher frequency of fragmented wakefulness and rapid eye movement REM sleep, and reduced locomotor activity” Administration of acetyl-L-carnitine was shown to improve these symptoms in mice61 A subsequent human trial found that narcolepsy patients given L-carnitine spent less total time in daytime sleep than patients who were given a placebo62


  1. ^ a b c d e f g h i j k l m n o p q r s t u "Narcolepsy Fact Sheet" NINDS NIH Publication No 03-1637 Retrieved 19 August 2016 
  2. ^ a b Goswami, Meeta; Thorpy, Michael J; Pandi-Perumal, S R 2016 Narcolepsy: A Clinical Guide 2 ed Springer p 39 ISBN 9783319237398 
  3. ^ a b "Narcolepsy Information Page" NINDS Retrieved 7 January 2017 
  4. ^ Harper, Douglas 2010 "Narcolepsy" Dictionarycom Online Etymology Dictionary Retrieved 19 August 2016 
  5. ^ a b c d e f g Green, Simon 2011 Biological rhythms, sleep, and hypnosis Basingstoke, Hampshire, England: Palgrave Macmillan ISBN 9780230252653 
  6. ^ Kandel, Eric R; Schwartz, James H; Jessell, Thomas M, eds 2000 Principles of Neural Science 4th ed McGraw-Hill p 949 ISBN 0-8385-7701-6 
  7. ^ Cunha, John P Shiel, Jr, William C, ed "Narcolepsy" MedicineNet Retrieved 15 March 2016 
  8. ^ Zorick, FJ; Salis, PJ; Roth, T; Kramer, M 1979 "Narcolepsy and automatic behavior: A case report" The Journal of Clinical Psychiatry 40 4: 194–7 PMID 422531 
  9. ^ "About Narcolepsy" Stanford Center for Narcolepsy Retrieved 15 January 2016 
  10. ^ Scammell Thomas E 2015 "Narcolepsy" N Engl J Med 373: 2654–2662 doi:101056/NEJMra1500587 
  11. ^ Nevsimalova, Sona 2014 "The Diagnosis and Treatment of Pediatric Narcolepsy" Current Neurology and Neuroscience Reports 14 8 doi:101007/s11910-014-0469-1 ISSN 1528-4042 
  12. ^ a b c d e f g h i j Mahlios J, De la Herrán-Arita AK, Mignot E October 2013 "The autoimmune basis of narcolepsy" Curr Opin Neurobiol 23 5: 767–773 doi:101016/jconb201304013 PMC 3848424  PMID 23725858 Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, hypnagonic hallucinations, sleep paralysis, and disturbed nocturnal sleep patterns 
  13. ^ a b c d e Malenka RC, Nestler EJ, Hyman SE 2009 "Chapter 12: Sleep and Arousal" In Sydor A, Brown RY Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd ed New York: McGraw-Hill Medical pp 294–296, 303 ISBN 9780071481274 the loss of orexin neurons raise the interesting possibility that narcolepsy may be caused by an autoimmune mediated destruction of these neurons in analogy with the autoimmune destruction of insulin-secreting β-islet cells in type I diabetes 
  14. ^ Klein J, Sato A; Sato September 2000 "The HLA system Second of two parts" N Engl J Med 343 11: 782–786 doi:101056/NEJM200009143431106 PMID 10984567 
  15. ^ a b c Mignot E 2001 "A commentary on the neurobiology of the hypocretin/orexin system" Neuropsychopharmacology 25 5 Suppl: S5–13 doi:101016/S0893-133X0100316-5 PMID 11682267 
  16. ^ Hallmayer, Joachim; Faraco, Juliette; et al 3 May 2009 "Narcolepsy is strongly associated with the T-cell receptor alpha locus" Nature Genetics 41 6: 708–711 doi:101038/ng372 PMC 2803042  PMID 19412176 
  17. ^ Singh, A K; Mahlios, J; Mignot, E Jun 2013 "Genetic association, seasonal infections and autoimmune basis of narcolepsy" J Autoimmun 43: 26–31 doi:101016/jjaut201302003 PMC 4118764  PMID 23497937 
  18. ^ Holm, Anja; Lin, Ling; Faraco, Juliette; Mostafavi, Sara; Battle, Alexis; Zhu, Xiaowei; Levinson, Douglas F; Han, Fang; Gammeltoft, Steen; Jennum, Poul; Mignot, Emmanuel; Kornum, Birgitte R 11 February 2015 "EIF3G is associated with narcolepsy across ethnicities" European Journal of Human Genetics 23 11: 1573–1580 doi:101038/ejhg20154 
  19. ^ a b Tsoukalas I 2012 "The origin of REM sleep: A hypothesis" Dreaming 22 4: 253–283 doi:101037/a0030790 
  20. ^ Vitelli, R 2013 Exploring the Mystery of REM Sleep Psychology Today, On-line blog, 25 March
  21. ^ "The MPA investigates reports of narcolepsy in patients vaccinated with Pandemrix" Swedish Medical Products Agency 18 August 2010 Retrieved 19 August 2010 
  22. ^ "Terveyden ja hyvinvoinnin laitos suosittaa Pandemrix-rokotusten keskeyttämistä" National Institute of Health and Welfare 24 August 2010 Retrieved 24 August 2010 
  23. ^ "Ties Between Big Pharma and THL Draw Complaints" Yle Uutiset 17 November 2010 Retrieved 15 March 2016 
  24. ^ "Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations: Results of a case inventory study by the MPA in Sweden during 2009‐2010" PDF Läkemedelsverket Medical Products Agency 30 June 2011 pp 1, 10 Retrieved 15 March 2016 
  25. ^ "Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults" Läkemedelsverket Medical Products Agency 26 March 2013 Retrieved 15 March 2016 
  26. ^ Li J, Hu Z, de Lecea L 2014 "The hypocretins/orexins: integrators of multiple physiological functions" Br J Pharmacol 171 2: 332–50 doi:101111/bph12415 PMC 3904255  PMID 24102345 The analgesic properties of orexin peptides have been well-established 
  27. ^ Malenka RC, Nestler EJ, Hyman SE 2009 "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin" In Sydor A, Brown RY Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2nd ed New York: McGraw-Hill Medical p 179 ISBN 9780071481274 Orexinergic projections in the CNS Orexin neurons with cell bodies in the lateral hypothalamic area LHA and posterior hypothalamus PH project throughout the brain excluding the cerebellum with dense projections to the noradrenergic locus ceruleus LC, histaminergic tuberomamillary nucleus TMN, serotonergic raphe nuclei, cholinergic laterodorsal and pedunculopontine nuclei LDT and PPT, and the dopaminergic ventral tegmental area VTA 
  28. ^ Thorpy MJ 1992 "The clinical use of the Multiple Sleep Latency Test The Standards of Practice Committee of the American Sleep Disorders Association" Sleep 15 3: 268–76 PMID 1621030 
  29. ^ "REM sleep deprivation during 5 hours leads to an immediate REM sleep rebound and to suppression of non-REM sleep intensity" Electroencephalogr Clin Neurophysiol 1990 Aug;762:114-22 National Institutes of Health 76: 114–22 Aug 1990 doi:101016/0013-46949090209-3 PMID 1697239 
  30. ^ "Narcolepsy Research - FAQs" Stanford Center for Narcolepsy Retrieved 15 January 2016 
  31. ^ Mignot, E; Lammers, GJ; et al 2002 "The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias" Archives of Neurology 59 10: 1553–1562 doi:101001/archneur59101553 PMID 12374492 
  32. ^ "About Hypersomnia" Hypersomnia Foundation 
  33. ^ a b c "International classification of sleep disorders, revised: Diagnostic and coding manual" PDF American Academy of Sleep Medicine 2001 Retrieved 25 January 2013 
  34. ^ Bassetti, C 1997 "Idiopathic hypersomnia A series of 42 patients" Brain 120 8: 1423–1435 doi:101093/brain/12081423 
  35. ^ a b c d e f Mignot EJ 2012 "A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes" Neurotherapeutics 9 4: 739–52 doi:101007/s13311-012-0150-9 PMC 3480574  PMID 23065655 
  36. ^ "Diagnosis of Idiopathic Hypersomnia/ Major Hypersomnolence Disorder" Retrieved 23 April 2013 
  37. ^ "Recent Updates to Proposed Revisions for DSM-5: Sleep-Wake Disorders" DSM-5 Development American Psychiatric Association 
  38. ^ Vernet, Cyrille 2009 "Narcolepsy with Long Sleep Time" Sleep 
  39. ^ "Modafinil marketed as Provigil: Serious Skin Reactions" Postmarketing Reviews 1 1 Fall 2007 Retrieved 15 March 2016 
  40. ^ Helmus, T; Rosenthal, L; Bishop, C; Roehrs, T; Syron, ML; Roth, T 1997 "The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals" Sleep 20 4: 251–7 PMID 9231950 
  41. ^ a b "XYREM® sodium oxybate" PDF United States Food and Drug Administration Jazz Pharmaceuticals, Inc 11 April 2014 Retrieved 9 August 2015 
  42. ^ "FDA Approval Letter for Xyrem; Indication: Cataplexy associated with narcolepsy; 17 Jul 2002" PDF 
  43. ^ Wise, MS; Arand, DL; Auger, RR; Brooks, SN; Watson, NF; American Academy of Sleep Medicine Dec 2007 "Treatment of narcolepsy and other hypersomnias of central origin" Sleep 30 12: 1712–27 PMC 2276130  PMID 18246981 
  44. ^ Boscolo-Berto, R; Viel, G; Montagnese, S; Raduazzo, DI; Ferrara, SD; Dauvilliers, Y October 2012 "Narcolepsy and effectiveness of gamma-hydroxybutyrate GHB: a systematic review and meta-analysis of randomized controlled trials" Sleep medicine reviews 16 5: 431–43 doi:101016/jsmrv201109001 PMID 22055895 
  45. ^ Gowda CR, Lundt LP; Lundt December 2014 "Mechanism of action of narcolepsy medications" CNS Spectrums 19 Supplement 1: 25–33 doi:101017/S1092852914000583 PMID 25403789 
  46. ^ Caputo F, Zoli G March 2007 "Treatment of narcolepsy with cataplexy" Lancet 369 9567: 1080–1 doi:101016/S0140-67360760522-4 PMID 17398302 
  47. ^ "NAMI, National Alliance on Mental Illness, Effexor, Common Side Effects" 
  48. ^ a b "Who Is At Risk for Narcolepsy" 
  49. ^ "Link Between Narcolepsy and Mental Health" Retrieved 6 June 2014 
  50. ^ "DH funds private prescriptions for drug denied to NHS patients" Health Service Journal 20 July 2015 Retrieved 20 July 2015 
  51. ^ "Hypersomnia Foundation - Treatment" 
  52. ^ a b Lynn Marie Trotti, MD 9 August 2010 "Flumazenil for the Treatment of Primary Hypersomnia" Emory University - Georgia Research Alliance ClinicalTrialsgov 
  53. ^ a b Lynn Marie Trotti, MD 15 June 2010 "Clarithromycin for the Treatment of Primary Hypersomnia" Emory University - Georgia Research Alliance ClinicalTrialsgov 
  54. ^ Rye, DB; Bliwise, DL; Parker, K; Trotti, LM; et al 21 November 2012 "Modulation of Vigilance in the Primary Hypersomnias by Endogenous Enhancement of GABAA Receptors" Sci Transl Med 4 161: 161ra151 doi:101126/scitranslmed3004685 PMID 23175709 
  55. ^ E Kelty; V Martyn; G O’Neil; G Hulse 19 February 2014 "Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report" Journal of Psychopharmacology 28 7: 703–706 doi:101177/0269881114523865 PMID 24554692 
  56. ^ Beck, Melinda 2012-12-10 "Scientists Try to Unravel the Riddle of Too Much Sleep" The Wall Street Journal 
  57. ^ "Hypersomnia Update" Emory University Retrieved 2014-04-22 
  58. ^ Trotti, L; et al June 2013 "Clarithromycin for the Treatment of Hypersomnia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial" Sleep 36 Abstract Supplement: A248 
  59. ^ Trotti, LM; Saini, P; Freeman, AA; Bliwise, DL; García, PS; Jenkins, A; Rye, DB 2013 "Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience" J Psychopharmacol Oxford 28 7: 697–702 doi:101177/0269881113515062 PMID 24306133 
  60. ^ Miyagawa, T; Miyadera, H; Tanaka, S; Kawashima, M; Shimada, M; Honda, Y; Tokunaga, K; Honda, M 2011 "Abnormally low serum acylcarnitine levels in narcolepsy patients" Sleep 34 3: 349–53A PMC 3041711  PMID 21358852 
  61. ^ Miyagawa, T; Honda, M; Kawashima, M; Shimada, M; Tanaka, S; Honda, Y; Tokunaga, K 30 April 2009 "Polymorphism located between CPT1B and CHKB, and HLA-DRB11501-DQB10602 haplotype confer susceptibility to CNS hypersomnias essential hypersomnia" PLoS ONE 4 4: e5394 Bibcode:2009PLoSO45394M doi:101371/journalpone0005394 PMC 2671172  PMID 19404393 
  62. ^ Miyagawa, T; Kawamura, H; Obuchi, M; Ikesaki, A; Ozaki, A; Tokunaga, K; Inoue, Y; Honda, M 2013 "Effects of oral L-carnitine administration in narcolepsy patients: A randomized, double-blind, cross-over and placebo-controlled trial" PLoS ONE 8 1: e53707 Bibcode:2013PLoSO853707M doi:101371/journalpone0053707 PMC 3547955  PMID 23349733 


  • Mitler MM, Hajdukovic R; Hajdukovic June 1991 "Relative Efficacy of Drugs for the Treatment of Sleepiness in Narcolepsy" Sleep 14 3: 218–20 PMC 2246380  PMID 1680245 
  • Chabas D, Taheri S, Renier C, Mignot E; Taheri; Renier; Mignot October 2003 "The Genetics of Narcolepsy" Annual Review of Genomics and Human Genetics 4: 459–83 doi:101146/annurevgenom4070802110432 PMID 14527309 CS1 maint: Multiple names: authors list link
  • Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP; Jackson; Neufing; McEvoy; Gordon 2004 "A functional autoantibody in narcolepsy" Lancet 364 9451: 2122–4 doi:101016/S0140-67360417553-3 PMID 15589310 CS1 maint: Multiple names: authors list link

External linksedit

  • ICD-10: G474
  • ICD-9-CM: 347
  • OMIM: 161400
  • MeSH: D009290
  • DiseasesDB: 8801
External resources
  • MedlinePlus: 000802
  • eMedicine: neuro/522
  • Narcolepsy Fact Sheet: National Institute of Neurological Disorders and Stroke
  • NARCOLEPSY: NOT ALONE international campaign by Project Sleep
  • Narcolepsy UK
  • Narcolepsy website from the Harvard Medical School Division of Sleep Medicine

narcolepsy, narcolepsy and driving, narcolepsy causes, narcolepsy meaning, narcolepsy medication, narcolepsy network, narcolepsy symptoms, narcolepsy test, narcolepsy treatment, narcolepsy with cataplexy

Narcolepsy Information about


  • user icon

    Narcolepsy beatiful post thanks!


Narcolepsy viewing the topic.
Narcolepsy what, Narcolepsy who, Narcolepsy explanation

There are excerpts from wikipedia on this article and video

Random Posts

Modern philosophy

Modern philosophy

Modern philosophy is a branch of philosophy that originated in Western Europe in the 17th century, a...
Tim Shadbolt

Tim Shadbolt

Timothy Richard "Tim" Shadbolt born 19 February 1947 is a New Zealand politician He is the Mayor of ...
HK Express

HK Express

Andrew Cowen Deputy CEO Website wwwhkexpresscom HK Express Traditional Chinese 香港快運航空...
List of shrinking cities in the United States

List of shrinking cities in the United States

The following municipalities in the United States have lost at least 20% of their population, from a...